Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$56.33 USD

56.33
1,338,701

+0.22 (0.39%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $56.32 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

    Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

    Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

      Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View

      Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.

        What's in the Offing for Regeneron (REGN) in Q1 Earnings?

        Investors are expected to focus on Eylea's performance and Dupixent's uptake when Regeneron Pharmaceuticals, Inc. (REGN) reports first-quarter 2018 results on May 3.

          Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark

          Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.

            BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat

            BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.

              Amgen (AMGN) Earnings Beat Estimates in Q1, Revenues Up Y/Y

              Amgen (AMGN) impresses with better-than-estimated results on both counts but tweaks its sales guidance for 2018. Shares decline in after-hours trading.

                Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

                Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

                  Shire (SHPG) Turns Down Takeda's Third Buyout Proposition

                  Shire (SHPG) declines Takeda Pharmaceutical's third acquisition offer in a cash-stock deal.

                    Sanofi to Divest European Generic Unit, Streamline Business

                    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

                      Mark Vickery headshot

                      Top Analyst Reports for AbbVie, Berkshire & PepsiCo

                      Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Berkshire Hathaway (BRK.B) and PepsiCo (PEP).

                        Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                        Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                          Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

                          The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.

                            Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU

                            Sanofi's (SNY) filing for its antibody cemiplimab for skin cancer and the label expansion of its marketed drug Dupixent for asthama wins acceptance from EMA.

                              EMA Accepts Regeneron/Sanofi's application for Dupixent

                              Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.

                                3 Sell-Rated Drug Stocks Investors Should Avoid for Now

                                Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.

                                  Kinjel Shah headshot

                                  4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                                  The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                                    Amgen's Repatha Gains CHMP Nod to Include Outcomes Data

                                    Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

                                      Immune Design Poised on Progress of Pipeline Candidates

                                      Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.

                                        Is Sanofi (SNY) a Great Stock for Value Investors?

                                        Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

                                          The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery

                                          The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery

                                            Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4

                                            Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.

                                              Sweta Jaiswal headshot

                                              Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

                                              Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

                                                Mark Vickery headshot

                                                Top Research Report for AT&T, Goldman Sachs & Sanofi

                                                Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Goldman Sachs (GS) and Sanofi (SNY).

                                                  Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy

                                                  The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.